Mitchell E. Levinson bought $70k of PLSE
Chief Strategy Officer at Pulse Biosciences, Inc.. 30,780 shares at an average of $2.27, traded Oct 7, 2022, filed Oct 11, 2022.
Score components
- +15RoleOfficer
- +8Trade size$70k at market
- +10Relative to holdingsHoldings up 82%
- +8Price context92% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.1%, 3m +78.8%, 6m +117.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001387131-22-010379, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 7, 2022 | POpen-market purchase Common Stock | +8,770 | $2.29 | $20k | 46,274 | Oct 11, 2022 |
| Oct 7, 2022 | POpen-market purchase Common Stockindirect: Spouse | +8,810 | $2.27 | $20k | 12,945 | Oct 11, 2022 |
| Oct 7, 2022 | POpen-market purchase Common Stockindirect: Immediate family member | +4,400 | $2.26 | $9,944 | 5,134 | Oct 11, 2022 |
| Oct 7, 2022 | POpen-market purchase Common Stockindirect: Immediate family member | +4,500 | $2.23 | $10k | 5,234 | Oct 11, 2022 |
| Oct 7, 2022 | POpen-market purchase Common Stockindirect: Immediate family member | +4,300 | $2.29 | $9,847 | 5,034 | Oct 11, 2022 |
Related signals
Other insiders at Pulse Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | PLSEbuy Pulse Biosciences, Inc. | Liane Rae Teplitsky Chief Operating Officer | $100k 2,025 shares | +98% | |
| 38Weak | PLSEbuy Pulse Biosciences, Inc. | Liane Rae Teplitsky Chief Operating Officer | $100k 2,070 shares | - | |
| 47Moderate | Pulse Biosciences, Inc. | Robert W Duggan director, owner | $13M 660,233 shares | +1% | |
| 47Moderate | Pulse Biosciences, Inc. | Robert W Duggan director, owner | $13M 660,233 shares | +1% | |
| 59Moderate | Pulse Biosciences, Inc. | Paul A Laviolette Chief Executive Officer | $295k 15,000 shares | - | |
| 61Notable | Pulse Biosciences, Inc. | Paul A Laviolette Chief Executive Officer | $295k 15,000 shares | +1773% | |
| 0Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $118k 5,000 shares | -10% | |
| 25Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $1.4M 60,000 shares | -95% | |
| 25Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $1.4M 60,000 shares | -95% | |
| 0Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $85k 4,600 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.